China Biopharmaceutical Industry Report, 2005-2006
  • Oct/2005
  • Hard Copy
  • USD $1,100
  • Pages:81
  • Single User License
    (PDF Unprintable)       
  • USD $1,200
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,800
  • Hard Copy + Single User License
  • USD $1,300
      

The report is classified into five parts, as follows:

1. Macro information on China's biopharmaceutical industry

China's macroeconomic environment analysis; China's policies and regulations on biopharmaceutical industry; China's access to WTO and its influence on China's biopharmaceutical industry; biopharmaceutical industrial technology level, developing situation and trends at home and abroad.

2. The global biopharmaceutical market

Current R&D trends of the global biopharmaceutical industry; global biopharmaceutical market analysis before and in 2005, including: market scale, sales status, products and enterprises analysis.

3. In-depth perspectives on China's biopharmaceutical industry and market

Quantitative and qualitative analysis of China's biopharmaceutical production and market sales characteristics before and in 2005; problems existing in China's biopharmaceutical industry; analysis on biological engineering, biological vaccine, diagnosis reagent and IFN markets; the status of China's biopharmaceutical operations;

4. Biotechnology development and market trends

The latest development trends and advanced management systems. Market forecast on China's biopharmaceutical market in 2006, including: factors influencing China's biopharmaceutical industry development in 2006, China's biopharmaceutical market variables in 2006, and future development of China's biopharmaceutical industry. 

5. Investment suggestions

Investment feasibility analysis, risk analysis, profitability analysis and products development suggestions.

 

1.Macro environment of China's biopharmaceutical industry in 2005 
1.1 Social and economy development
1.1.1 China national economy analysis and forecast, 2005-2006 
1.1.2 China's pharmaceutical operations in 2005
1.2 Population environment analysis
1.2.1 Demography over past years
1.2.2 Population aging and its influences
1.2.3 Residents' income and consumption
1.2.4 Residents' disease spectrum and medical consumption changes
1.3 Residents' medical consumption structure 
1.3.1 Chinese urban and rural medical consumption structure
1.3.2 Per capita medical treatment expenses and variables 

2.The political environment of Chin's biopharmaceutical industry in 2006
2.1 China's medical regulatory system analysis
2.1.1 Government control on medical industry 
2.1.2 Establishment of the national medical system
2.1.3 GMP certification
2.1.4 GSP certification for drug enterprises
2.1.5 GAP certification for Chinese traditional medicine 
2.1.6 GCP police for new drug experiments
2.1.7 International GLP accreditation advanced in China
2.1.8 MOH's administrative and regulatory measures to medical industry in 2005 
2.2 China's medical treatment system reform and its influences
2.2.1 Basic urban medical insurance system  
2.2.2 Rural medical treatment system improvements
2.2.3 Commercial medical insurance system establishment and its influences 
2.4 Medicine intellectual property right protections
2.4.1 Fake and patent drugs
2.4.2 WTO related clauses 
2.4.3 The intellectual property right protection of Chinese traditional medicine 
2.5 Medical open-up policy after China's access to WTO
2.5.1 Commitments on medical products after China's access to WTO 
2.5.2 Related policies for foreign investments in medical manufacturing 

3.Technological environment analysis of China's biopharmaceutical industry in 2006
3.1 The global development of basic medical science in 2005 and perspectives on 2006
3.1.1 Global medical research and development in 2005
3.1.2 Analysis of failed cases on global medical research, 2004-2005
3.1.3 Global medical market hotspots forecast in 2006
3.1.4 WHO's 6 drug categories prior to be developed 
3.2 China's medical development
3.2.1 China's basic medical science development
3.2.2 Medical products development in china
3.2.3 Medicine certification in China, 2004-2005
3.2.4 New medical research hotspots in China in 2006

4.China's biopharmaceutical industry investment
4.1 Investment characteristics
4.1.1 Growth analysis 
4.1.2 Profitability analysis 
4.1.3 Investment barriers analysis 
4.1.4 Investment risk analysis 
4.2 Investments in China's Pharmaceuticals industry in 2005
4.2.1 New and under-process projects 
4.2.2 Investment fund sources and allocation 
4.2.3 Investment returns and existing problems 
4.3 Investment forecast in 2006
4.3.1 Investment scale forecast
4.3.2 Investment distribution forecast
4.3.3. Investment return forecast

5.The global biopharmaceutical market in 2005
5.1 The current biopharmaceutical R&D trends
5.2 Global biopharmaceutical industrial characteristics 

6.China's biopharmaceutical industry development

6.1 China's biopharmaceutical industry operations in 2005
6.1.1 Operation 
6.1.2 Market characteristics
6.2 Existing problems

7.Biopharmaceutical products analysis
7.1 Genetic engineering products
7.1.1 Genetic engineering application and medical innovations
7.1.2 Status quo of China’s genetic engineering products
7.1.3 R&D strength survey of China's genetic engineering enterprises
7.1.4 Genetic engineering prospects
7.2 Biological vaccine
7.2.1 China's vaccines market 
7.2.2 Vaccines market potentials
7.3 Biological diagnosis reagent
7.4 Interferon 

8.China's biopharmaceutical enterprises analysis
8.1 Enterprises rank
8.1.1 Sales of the top 10 biopharmaceutical enterprises in 2005
8.1.2 Sales of the top 200 Biopharmaceutical enterprises in 2004 according to NBSC
8.1.3 Profit of the top 200 Biopharmaceutical enterprises in 2004 according to NBSC
8.2 Operations of listed biopharmaceutical enterprises

9.Biological technology analysis
9.1 The development trends of the global biotechnology and industry
9.1.1 American biotechnology industry is reviving  
9.1.2 Constant growth of biopharmaceutical sales in the world
9.1.3 Continued plant area expansion of the transgenic crops 
9.1.4 Systematization and comprehension of biological technology 
9.1.5 Scientists succeeded in SARS breakthrough
9.2 Biotechnology research and industrialization 
9.2.1 America NIH 
9.2.2 Europe 
9.2.3 Japan
9.2.4 Other countries 
9.3 The latest Biotechnology developments

10.Market forecast on China's biopharmaceutical in 2006 
10.1 Analysis of factors influences China’s biopharmaceutical industry development
10.2 China's biopharmaceutical industry development in 2006 and next ten years
10.3 Perspectives on China's biopharmaceutical industry 
10.3.1 Opportunity brought by biopharmaceutical R&D 
10.3.2 Price down and medical market is thereby further expansive
10.3.3 Market forecast 
10.3.4 International trade 

11.Investment suggestion
11.1 Investment blanks
11.2 Investment orientation
Proportion of the global listed biopharmaceutical companies in 2004 
Pharmaceutical and genetic engineering medical market of America, Japan, German and China
Genetic engineering products with sale volume of US$1-3.5 billion in the world 
The sales scale of biopharmaceuticals products, 1996-2004 
Annual average growth rate of biopharmaceuticals products, 1996-2004
Biopharmaceutical products and vaccines launched from 1982 to 2002 
Biopharmaceutical products launched in America in 2004 
Sales statistics of genetic engineering products in Japan
Genetic engineering manufacturers in China
Three stages of China’s genetic engineering development
Sales of China’s genetic engineering products 
China’s per capita albumin consumption
China’s GMP blood producers 
Expenses diversions involved in prevention and immunity 
The three vaccines common-used for children in China
Major cancers and death rate caused of cancers in China, 1973-2002 
China’s government input in biotechnology for recent 10 years

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号